Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT01891318
Other study ID # CASE7312
Secondary ID
Status Recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date July 3, 2013
Est. completion date December 1, 2024

Study information

Verified date January 2024
Source Case Comprehensive Cancer Center
Contact Erin Murphy, MD
Phone 1-866-223-8100
Email TaussigResearch@ccf.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This Phase I/II trial studies the ability to stop brain metastases from coming back after treatment with radiosurgery followed by surgical resection. It will also evaluate the side effects of these combined treatments and help determine the best radiosurgery dose. Radiosurgery focuses the x-rays directly to the tumor and cause less damage to the normal tissue in the brain.


Description:

PRIMARY OBJECTIVES: I. To determine the safety (risk of acute and long-term toxicities) of neoadjuvant radiosurgery at escalating doses followed by surgical resection of brain metastases. (Phase I) II. To determine the local control of brain metastases treated with neoadjuvant radiosurgery followed by surgical resection. (Phase II) SECONDARY OBJECTIVES: I. To determine the rate of distant brain failure when brain metastases are managed with neoadjuvant radiosurgery followed by surgical resection. II. To estimate the rate of salvage surgery, whole brain radiation therapy (WBRT), or stereotactic radiosurgery (SRS) for participants treated with neoadjuvant radiosurgery followed by surgical resection. III. To determine the rate of radiation necrosis/steroid dependency. IV. To determine the radiobiologic impact of neoadjuvant radiosurgery for resected brain metastases. OUTLINE: This is a phase I, dose-escalation study of radiosurgery followed by a phase II study. The following outcomes were removed from the protocol in an amendment: - Changes in neurocognitive function as measured by the Hopkins Verbal Learning Test (HVLT), Controlled Oral Word Association (COWA) & Trailmaking Test B, and Trailmaking Test A - QOL measured by FACT-BR and EORTC-QLQ30


Recruitment information / eligibility

Status Recruiting
Enrollment 36
Est. completion date December 1, 2024
Est. primary completion date December 1, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Have a prior histologic diagnosis of cancer other than small cell lung cancer, lymphoma, and germ cell histologies - Magnetic resonance imaging (MRI) evidence of 1-4 brain metastases, with at least one lesion > 20 mm and = 50 mm in maximal diameter and determined to be appropriate for SRS and gross total resection; all other brain metastases are appropriate for SRS - Patient can have prior SRS to lesions other than the one planned for neoadjuvant SRS and resection - Patient must have a Karnofsky performance score of = 70 Exclusion Criteria: - Patient deemed medically unfit to undergo surgical resection of brain metastasis - Prior whole brain radiotherapy - Patient with contraindication for imaging with MRI - Inability to participate in study activities due to physical or mental limitations - Inability or unwillingness to return for all the required follow-up visits - At the time of planning, unable to deliver 10 Gray (Gy) or less to optic nerve/chiasm - Tumor located in the brainstem - Imaging or cytologic evidence of leptomeningeal disease

Study Design


Related Conditions & MeSH terms


Intervention

Radiation:
radiosurgery
Undergo radiosurgery
Procedure:
therapeutic conventional surgery
Undergo surgical resection
quality-of-life assessment
Ancillary studies

Locations

Country Name City State
United States Cleveland Clinic, Case Comprehensive Cancer Center Cleveland Ohio
United States University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center Cleveland Ohio

Sponsors (1)

Lead Sponsor Collaborator
Case Comprehensive Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Maximum tolerated dose (MTD) MTD of radiosurgery determined by dose-limiting toxicities graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.0 (Phase I) Day 0
Primary Proportion of participants without local failure (Phase II) Local control of brain metastases, as measured by proportion of participants without local failure (Local failure is tumor progression of the metastasis treated on the study)
(Phase II)
The Kaplan-Meier method will be used.
Up to 3 years
Secondary Proportion of participants with distant brain failure Rate of distant brain failure, defined as progression of brain metastases outside of the brain metastasis treated on study. The Kaplan-Meier method will be used. Up to 3 years
Secondary Rate of radiation necrosis/steroid dependency Rate of radiation necrosis/steroid dependency Up to 3 years
Secondary Rate of salvage treatment Number of patients that have any salvage treatment, including surgery, stereotactic radiosurgery (SRS), or whole brain radiation therapy (WBRT) Up to 3 years
See also
  Status Clinical Trial Phase
Completed NCT02107755 - Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma Phase 2
Terminated NCT01217411 - RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer Phase 1
Completed NCT00098605 - Lapatinib in Treating Brain Metastases in Patients With Stage IV Breast Cancer and Brain Metastases Phase 2
Completed NCT00072163 - Temozolomide and Thalidomide in Treating Patients With Brain Metastases Secondary to Melanoma Phase 2
Completed NCT01703507 - Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma Phase 1
Completed NCT00033254 - Radiation Therapy With or Without Thalidomide in Treating Patients With Brain Metastases Phase 3
Active, not recruiting NCT01706432 - Hypofractionated Image Guided Radiation Therapy in Treating Patients With Stage IV Breast Cancer
Suspended NCT01843413 - Stereotactic Radiosurgery in Treating Patients With Large Brain Metastases N/A
Completed NCT01276210 - Sorafenib Tosylate and Stereotactic Radiosurgery in Treating Patients With Brain Metastases Phase 1
Completed NCT01234740 - Bafetinib in Treating Patients With Recurrent High-Grade Glioma or Brain Metastases Phase 1
Completed NCT02312622 - Phase 2 Etirinotecan Pegol in Refractory Brain Metastases & Advanced Lung Cancer / Metastatic Breast Cancer Phase 2
Terminated NCT00937482 - Cediranib Maleate and Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer Phase 1
Terminated NCT02269111 - Quantitative MRI in Assessing Disease in Patients With Brain Tumors N/A
Withdrawn NCT02277561 - Voxel Based Diffusion Tensor Imaging in Predicting Response in Patients With Brain Metastases Undergoing Whole Brain Radiation Therapy or Stereotactic Radiosurgery N/A
Completed NCT00992602 - Liposomal Cytarabine and High-Dose Methotrexate in Treating Patients With Central Nervous System Metastases From Breast Cancer Phase 2
Withdrawn NCT02145910 - Vemurafenib Combined With Whole Brain Radiation Therapy or Radiosurgery in Patients With BRAF Mutation-Positive Melanoma and Brain Metastases Phase 1